These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1952 related articles for article (PubMed ID: 18815398)

  • 1. Lung cancer.
    Herbst RS; Heymach JV; Lippman SM
    N Engl J Med; 2008 Sep; 359(13):1367-80. PubMed ID: 18815398
    [No Abstract]   [Full Text] [Related]  

  • 2. A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
    Yagui-Beltrán A; Jablons DM
    Ann Thorac Cardiovasc Surg; 2009 Aug; 15(4):213-20. PubMed ID: 19763051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances of heterogeneity of EGFR in non-small cell lung cancer].
    Zheng H; Zhang H; Shi H; Li B
    Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):890-3. PubMed ID: 22104226
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer].
    Wang X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):541-545. PubMed ID: 31451147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of smoking induced non-small cell lung carcinogenesis by decreasing ERBB pathway-related microRNA expression.
    Zhang L; Wang H; Wang C
    Thorac Cancer; 2019 Apr; 10(4):890-897. PubMed ID: 30868748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving Treatment Options for Lung Cancer.
    Morgensztern D; Herbst RS
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
    [No Abstract]   [Full Text] [Related]  

  • 7. Establishment and characterization of primary lung cancer cell lines from Chinese population.
    Zheng C; Sun YH; Ye XL; Chen HQ; Ji HB
    Acta Pharmacol Sin; 2011 Mar; 32(3):385-92. PubMed ID: 21372829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 9. [Molecular pathogenesis of lung cancers and the preservative therapy].
    Shimizu E
    Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):562-8. PubMed ID: 15052821
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.
    Dietrich S; Uppalapati R; Seiwert TY; Ma PC
    J Environ Pathol Toxicol Oncol; 2005; 24(3):149-62. PubMed ID: 16050800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.
    Johnson BE
    Chest; 1995 Jun; 107(6 Suppl):287S-290S. PubMed ID: 7781407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling.
    Pillai S; Rizwani W; Li X; Rawal B; Nair S; Schell MJ; Bepler G; Haura E; Coppola D; Chellappan S
    Mol Cell Biol; 2011 Jul; 31(14):3052-67. PubMed ID: 21606196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
    Zhou W; Zhang W; Han B
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):118-126. PubMed ID: 32093456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):796-9. PubMed ID: 26813604
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
    Zhang J; Park D; Shin DM; Deng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
    Zhang S; Sun Y
    EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.
    Zheng R; Shen Q; Mardekian S; Solomides C; Wang ZX; Evans NR
    J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e71-e79. PubMed ID: 32007245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
    Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun SY
    Theranostics; 2021; 11(8):3964-3980. PubMed ID: 33664875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line.
    Reeve JG; Rabbitts PH; Twentyman PR
    Br J Cancer; 1990 Jun; 61(6):851-5. PubMed ID: 1973619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 98.